We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The Phase 1 study evaluates the safety and pharmacokinetics of MM-121 when administered in combination with these separate chemotherapy regimens. Study sites in North America and the European Union are expected to participate in this trial. The first patient was enrolled at Fox Chase Cancer Center in Philadelphia, PA.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

Advertisement